Open AccessAntibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
Author(s) -
Katharina Pomej,
Lorenz Balcar,
Bernhard Scheiner,
Georg Semmler,
Tobias Meischl,
Mattias Mandorfer,
Thomas Reiberger,
Christian Müller,
Michael Trauner,
Matthias Pinter
Publication year - 2021
Publication title -
journal of hepatocellular carcinoma
Language(s) - English
Resource type - Journals
ISSN - 2253-5969
DOI - 10.2147/jhc.s317957
Subject(s) - medicine , sorafenib , rifaximin , hepatocellular carcinoma , gastroenterology , antibiotics , liver function , liver cancer , microbiology and biotechnology , biology
Antibiotic treatment (ABT) affects the outcome of cancer patients treated with immune checkpoint inhibitors (ICIs) and chemotherapy, possibly by altering the gut microbiome. We investigated the impact of ABT on overall survival (OS) and progression-free survival (PFS) in patients with advanced HCC treated with sorafenib.